VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug (IND) approval from the U.S.
Assays were also received for a 3-hole, 360-metre reverse circulation drilling program over the southern extent of the Kamperman deposit at Feysville, with best results grading up to 6 metres at 1.04 ...
Climate change is making us sick — and the healthcare system is exacerbating the problem. But new strategies suggest it’s possible to clean up our act.
Looking to make a name for yourself in the digital art world? Then you’re in luck – building an online art store and marketing your products has never been ...